- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
CCM Research analyst, Mohammad Sharifzadeh, PhD, CFA, has written an update report on Starpharma Holdings.
Starpharma Holdings, Ltd. (SPHRY: OTCQX) is an Australian-based company engaged in the development and application of dendrimer nanotechnologies as drugs and in other life science applications. Starpharma's business strategy is to use dendrimer-based nanotechnology to discover, develop and commercialize pharmaceuticals for serious human diseases and in life sciences.
In the report the analyst states that "SPHRY's lead dendrimer product, VivaGel™, addresses markets with huge potentials and stands at the forefront of global HIV/AIDS prevention strategies."
The analyst continues to state that "Starpharma has a healthy balance sheet. They have a strong cash position which can support their operating and R&D expenses should there be a shortfall in revenues. Starpharma has almost a debt free balance sheet with substantial equity which provides the company with the opportunity of external financing should the need arises." A free copy of the report can be found at http://www.ccmopportunitybase.com .
CCM Research subscribes to the "Standards for Independent Research Providers" and the principles contained in the Analyst/Corporate Issuer Guidelines jointly promulgated by the CFA Institute and the National Investor Relations Institute, described at: http://www.cfainstitute.org and http://www.niri.org .
About CCM Research
CCM Research, is a division of Cronus Capital Markets, Inc. Cronus Capital Markets, Inc., through its CCM Consulting division, entered into a one year $30,000.00 contract with the Company to assist it with the creation and execution of information-based strategies to overcome market inefficiencies that are commonplace for the vast majority of public companies; such as share illiquidity and stagnant market presence.
Cronus Capital Markets (CCM) is a global investment information firm who strategically produces and introduces, through various forms of analytics and worldwide distribution, information on equity market opportunities. CCM’s equity indexes receive international attention and represent important new benchmarks of growth.
For more information, please click here
Cronus Capital Markets
Dianne Rudderham, 416-368-3700 ext 223
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
FEI Company: Strong Growth Prospects Remain May 1st, 2015
Arrowhead to Present at Upcoming Conferences April 28th, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Testing Facility for Graphene Enhanced Composite Pipes May 5th, 2015